Pharvaris BV (NASDAQ:PHVS) — Market Cap & Net Worth
Market Cap & Net Worth: Pharvaris BV (PHVS)
Pharvaris BV (NASDAQ:PHVS) has a market capitalization of $1.82 Billion ($1.82 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6632 globally and #1950 in its home market, demonstrating a 7.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharvaris BV's stock price $29.44 by its total outstanding shares 64959454 (64.96 Million). Analyse PHVS operating cash flow to see how efficiently the company converts income to cash.
Pharvaris BV Market Cap History: 2021 to 2026
Pharvaris BV's market capitalization history from 2021 to 2026. Data shows growth from $934.77 Million to $1.91 Billion (0.29% CAGR).
Index Memberships
Pharvaris BV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.08% | #165 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #710 of 3165 |
Weight: Pharvaris BV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pharvaris BV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharvaris BV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PHVS by Market Capitalization
Companies near Pharvaris BV in the global market cap rankings as of May 4, 2026.
Key companies related to Pharvaris BV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Pharvaris BV Historical Marketcap From 2021 to 2026
Between 2021 and today, Pharvaris BV's market cap moved from $934.77 Million to $ 1.91 Billion, with a yearly change of 0.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.91 Billion | +6.09% |
| 2025 | $1.80 Billion | +44.76% |
| 2024 | $1.25 Billion | -31.66% |
| 2023 | $1.82 Billion | +149.33% |
| 2022 | $730.79 Million | -21.82% |
| 2021 | $934.77 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Pharvaris BV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.82 Billion USD |
| MoneyControl | $1.82 Billion USD |
| MarketWatch | $1.82 Billion USD |
| marketcap.company | $1.82 Billion USD |
| Reuters | $1.82 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema… Read more